MX2013006418A - Derivados de oxazolil-metileter como agonistas del receptor de alx. - Google Patents

Derivados de oxazolil-metileter como agonistas del receptor de alx.

Info

Publication number
MX2013006418A
MX2013006418A MX2013006418A MX2013006418A MX2013006418A MX 2013006418 A MX2013006418 A MX 2013006418A MX 2013006418 A MX2013006418 A MX 2013006418A MX 2013006418 A MX2013006418 A MX 2013006418A MX 2013006418 A MX2013006418 A MX 2013006418A
Authority
MX
Mexico
Prior art keywords
oxazolyl
receptor agonists
alx receptor
methylether derivatives
methylether
Prior art date
Application number
MX2013006418A
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2013006418A publication Critical patent/MX2013006418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La invención se refiere a derivados de oxazolil-metiléter de fórmula (I), donde R1, R2, R3, R4 y R5 son como se define en la descripción, a su preparación y a su uso como compuestos farmacéuticamente activos.
MX2013006418A 2010-12-07 2011-12-06 Derivados de oxazolil-metileter como agonistas del receptor de alx. MX2013006418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2010055616 2010-12-07
PCT/IB2011/055487 WO2012077049A1 (en) 2010-12-07 2011-12-06 Oxazolyl-methylether derivatives as alx receptor agonists

Publications (1)

Publication Number Publication Date
MX2013006418A true MX2013006418A (es) 2013-07-15

Family

ID=45444667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006418A MX2013006418A (es) 2010-12-07 2011-12-06 Derivados de oxazolil-metileter como agonistas del receptor de alx.

Country Status (19)

Country Link
US (1) US8846733B2 (es)
EP (1) EP2649068B1 (es)
JP (1) JP5923107B2 (es)
KR (1) KR101864463B1 (es)
CN (1) CN103261194B (es)
AR (1) AR084173A1 (es)
AU (1) AU2011340146B2 (es)
CA (1) CA2816376C (es)
CY (1) CY1116004T1 (es)
DK (1) DK2649068T3 (es)
ES (1) ES2526132T3 (es)
HR (1) HRP20150049T1 (es)
MX (1) MX2013006418A (es)
PL (1) PL2649068T3 (es)
PT (1) PT2649068E (es)
RU (1) RU2588567C2 (es)
SI (1) SI2649068T1 (es)
TW (1) TWI523853B (es)
WO (1) WO2012077049A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640699B1 (en) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Bridged spiro[2,4]heptane ester derivatives
EP2850058B1 (en) 2012-05-16 2016-07-13 Actelion Pharmaceuticals Ltd. 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
AU2014292064B2 (en) 2013-07-18 2018-07-05 Idorsia Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
WO2015079692A1 (ja) 2013-11-28 2015-06-04 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
EP3331884B1 (en) 2015-05-27 2020-06-17 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CA3055093A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
PE20210046A1 (es) 2018-03-05 2021-01-08 Bristol Myers Squibb Co Agonistas de fenilpirrolidinona del receptor 2 de formil peptido

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
AU2001290258A1 (en) 2000-09-22 2002-04-02 Nihon Nohyaku Co. Ltd. N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
AU2003214249A1 (en) 2002-04-03 2003-10-13 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
KR20060130064A (ko) 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
US7939671B2 (en) 2007-08-21 2011-05-10 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
NZ586735A (en) * 2007-12-18 2012-06-29 Actelion Pharmaceuticals Ltd Aminotriazole derivatives as alx agonists
TWI490190B (zh) 2009-05-18 2015-07-01 Actelion Pharmaceuticals Ltd 橋聯螺〔２．４〕庚烷衍生物
CN101909306A (zh) * 2009-06-08 2010-12-08 中兴通讯股份有限公司 中继站管理方法及基站
WO2010143116A1 (en) * 2009-06-09 2010-12-16 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物

Also Published As

Publication number Publication date
DK2649068T3 (en) 2014-12-08
AR084173A1 (es) 2013-04-24
KR20130133240A (ko) 2013-12-06
JP2013544878A (ja) 2013-12-19
US20130261159A1 (en) 2013-10-03
CA2816376C (en) 2018-11-20
EP2649068A1 (en) 2013-10-16
US8846733B2 (en) 2014-09-30
PL2649068T3 (pl) 2015-03-31
CN103261194A (zh) 2013-08-21
KR101864463B1 (ko) 2018-06-04
TW201305151A (zh) 2013-02-01
TWI523853B (zh) 2016-03-01
PT2649068E (pt) 2014-12-23
ES2526132T3 (es) 2015-01-07
RU2013130879A (ru) 2015-01-20
AU2011340146B2 (en) 2016-05-19
CY1116004T1 (el) 2017-01-25
CA2816376A1 (en) 2012-06-14
JP5923107B2 (ja) 2016-05-24
RU2588567C2 (ru) 2016-07-10
EP2649068B1 (en) 2014-10-29
WO2012077049A1 (en) 2012-06-14
CN103261194B (zh) 2016-02-24
HRP20150049T1 (hr) 2015-02-27
SI2649068T1 (sl) 2015-01-30
AU2011340146A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
MY153985A (en) Aminotriazole derivatives as alx agonists
PH12014502540B1 (en) Benzimidazole-proline derivatives
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MY181898A (en) Heterocyclic compounds and uses thereof
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
MX348823B (es) Formulaciones estables de linaclotida.
MX342440B (es) Derivados fluorados de aminotriazol.
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
PH12015502118A1 (en) Pyridin-4-yl derivatives
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
UA116801C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MX2015017541A (es) Derivados de espiro [2.4] heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx.
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID

Legal Events

Date Code Title Description
FG Grant or registration